Christopher Jon Forlenza MD

PubMed

• Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.
  Seth E Karol, Seong L Khaw, C Michel Zwaan, Andre Baruchel, Henrique Bittencourt
  Pediatric Blood & Cancer. 2025-07-01
• Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
  Andrew E Place, Seth E Karol, Christopher J Forlenza, Todd M Cooper, Christopher Fraser
  Pediatric Blood & Cancer. 2025-06-01
• 1 citations
  Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era.
  Lianna J Marks, Victor Ritter, Jennifer E Agrusa, Kala Y Kamdar, Julie Rivers
  Blood Advances. 2025-03-25

Journal Articles

• KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.  
  Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC, Jounal of Clinical Oncology, 7/20/2016

Abstracts/Posters

• Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
  Christopher J. Forlenza, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018